CharleneMantiaMD

PubMed

• 4 citations
  An economic analysis comparing health care resource use and cost of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin versus gemcitabine and cisplatin a...
  Kamaneh Montazeri, G Dranitsaris, Jonathan David Thomas, C Curran, Mark A. Preston
  Urologic Oncology. 2021-06-20
• 19 citations
  Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067
  Meredith M. Regan, Charlene Mantia, Lillian Werner, Ahmad A. Tarhini, James Larkin
  Journal for Immunotherapy of Cancer. 2021-11-01
• 68 citations
  Predicting the higher rate of intracranial hemorrhage in glioma patients receiving therapeutic enoxaparin
  Charlene Mantia, Erik J. Uhlmann, Maneka Puligandla, Griffin M. Weber, Donna Neuberg
  Blood. 2017-06-22

Journal Articles

• Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients with Renal Cell Carcinoma  
  Praful Ravi, Charlene Mantia, Christopher Su, Neeraj Agarwal, Yousef Zakharia, Rana R Mckay, Vivek Narayan, Ajjai Alva, Bradley A Mcgregor, David F Mcdermott, Toni K C..., JAMA Oncology

Abstracts/Posters

• Recurrent Intracranial Hemorrhage and Venous Thromboembolism Following Initial Intracranial Hemorrhage in Patients with Brain Tumors on Anticoagulation
  Charlene Mantia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

• Sensitivity of treatment-free survival (TFS), a novel outcome, to subgroup analyses of patients (pts) with advanced melanoma (MEL) treated with immune checkpoint inhib... 
  2019 ASCO Annual Meeting - 6/1/2019